Nls pharmaceutics receives green light from the u.s. fda to proceed with phase 3 clinical program (amaze) for quilience(r) (mazindol er) for the treatment of narcolepsy

Zurich, switzerland / accesswire / may 2, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the u.s. food and drug administration (fda) provided authorization to proceed with the phase 3 program for quilience® (mazindol er).
NLSP Ratings Summary
NLSP Quant Ranking